-
Kizdar net |
Kizdar net |
Кыздар Нет
Blood–brain barrier dysfunction can contribute to pharmacoresistance …
Jul 3, 2014 · We tested the hypothesis that interstitial albumin can contribute to pharmacoresistance, which is common among …
Blood–brain barrier dysfunction can contribute to pharmacoresistance …
We tested the hypothesis that interstitial albumin can contribute to pharmacoresistance, which is common among patients with focal …
Blood–brain barrier dysfunction can contribute to pharmacoresistance …
Jun 1, 2014 · Blood–brain barrier (BBB) leakage occurs during epileptogenesis and several pieces of evidence suggest that this …
Blood–brain barrier dysfunction can contribute to pharmacoresistance …
We tested the hypothesis that interstitial albumin can contribute to pharmacoresistance, which is common among patients with focal …
Blood–brain barrier dysfunction can contribute to pharmacoresistance …
Jul 3, 2014 · We tested the hypothesis that interstitial albumin can contribute to pharmacoresistance, which is common among …
Significance: A dysfunctional BBB with acute extravasation of serum albumin into the brain’s interstitial space could contribute to …
Blood-brain barrier dysfunction can contribute to pharmacoresistance …
Jul 6, 2014 · We tested the hypothesis that interstitial albumin can contribute to pharmacoresistance, which is common among …
pubmed.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
Blood-brain barrier dysfunction can contribute to pharmacoresistance …
Salar, Seda ; Maslarova, Anna ; Lippmann, Kristina et al. / Blood-brain barrier dysfunction can contribute to pharmacoresistance of …
Recent studies indicated that blood-brain barrier (BBB) disruption is common among patients with pharmacoresistant focal epilepsies.
Skip to content
Accessibility Feedback